Chronic hepatitis C treatments are being withdrawn from the market as new drugs are released.

Roche's Pegasys, a treatment for hepatitis B and C infection, eventually withdrew from the Korean market.

Pegasys PFS products were revoked on the 8th. Pegasys, which was approved in Korea in 2004, was expected to be a hepatitis C treatment injection combined with Ribavirin, especially once a week. It was later used as a treatment for hepatitis B.

Sales of Pegasys which has been a blockbuster for more than ₩10 billion, dropped due to oral chronic hepatitis treatment. Last year's IQVIA sales stood at only ₩56.14 million.

DAA hepatitis C drugs released sin